Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 87 The United Laboratories International Holdings Limited Annual Report 2019 5. REVENUE AND SEGMENT INFORMATION (Continued) (i) Disaggregation of revenue from contracts with customers (Continued) For the year ended 31 December 2018 Intermediate Bulk Finished products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products 6-APA 885,876 – – 885,876 – 885,876 Antibiotics products – 3,377,887 1,855,358 5,233,245 – 5,233,245 Insulin Products – – 658,937 658,937 – 658,937 Others 347,749 11,823 372,956 732,528 – 732,528 Revenue from contracts with customers 1,233,625 3,389,710 2,887,251 7,510,586 – 7,510,586 Inter-segment sales 1,617,804 423,009 – 2,040,813 (2,040,813) – Segment revenue 2,851,429 3,812,719 2,887,251 9,551,399 (2,040,813) 7,510,586 All of the Group’s revenue is recognised at a point in time during the years ended 31 December 2019 and 2018. (ii) Performance obligations for contracts with customers The Group recognises revenue from the sale of pharmaceutical products, revenue is recognised when control of the goods has been transferred, being when the goods have been delivered to and received by the customer. (iii) Transaction price allocated to the remaining performance obligation for contracts with customers Contracts for sale of pharmaceutical products are typically non-cancellable. The contracts for sales of products have expected duration of one year or less. As permitted under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.